Yassine, HM;
Al-Jighefee, H;
Al-Sadeq, DW;
Dargham, SR;
Younes, SN;
Shurrab, F;
Marei, RM;
... Nasrallah, GK; + view all
(2021)
Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies.
International Journal of Infectious Diseases
, 102
pp. 181-187.
10.1016/j.ijid.2020.10.042.
Preview |
Text
Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies.pdf - Other Download (699kB) | Preview |
Abstract
Objectives: To evaluate and compare the performances of five commercial ELISA assays (EDI, AnshLabs, Dia.Pro, NovaTec, and Lionex) for detecting anti-SARS-CoV-2 IgG. / Methods: Seventy negative control samples (collected before the COVID-19 pandemic) and samples from 101 RT-PCR-confirmed SARS-CoV-2 patients (collected at different time points from symptom onset: ≤7, 8–14 and >14 days) were used to compare the sensitivity, specificity, agreement, and positive and negative predictive values of each assay with RT-PCR. A concordance assessment between the five assays was also conducted. Cross-reactivity with other HCoV, non-HCoV respiratory viruses, non-respiratory viruses, and nuclear antigens was investigated. / Results: Lionex showed the highest specificity (98.6%; 95% CI 92.3–99.8), followed by EDI and Dia.Pro (97.1%; 95% CI 90.2–99.2), NovaTec (85.7%; 95% CI 75.7–92.1), then AnshLabs (75.7%; 95% CI 64.5–84.2). All ELISA kits cross-reacted with one anti-MERS IgG-positive sample, except Lionex. The sensitivity was low during the early stages of the disease but improved over time. After 14 days from symptom onset, Lionex and NovaTec showed the highest sensitivity at 87.9% (95% CI 72.7–95.2) and 86.4% (95% CI 78.5–91.7), respectively. The agreement with RT-PCR results based on Cohen's kappa was as follows: Lionex (0.89) > NovaTec (0.70) > Dia.Pro (0.69) > AnshLabs (0.63) > EDI (0.55). / Conclusion: The Lionex and NovaLisa IgG ELISA kits, demonstrated the best overall performance.
| Type: | Article |
|---|---|
| Title: | Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies |
| Location: | Canada |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ijid.2020.10.042 |
| Publisher version: | https://doi.org/10.1016/j.ijid.2020.10.042 |
| Language: | English |
| Additional information: | Copyright © 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | COVID-19, SARS-CoV-2, Serology, IgG, ELISA, Sensitivity, Specificity |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10172381 |
Archive Staff Only
 |
View Item |
